Zanubrutinib for untreated CLL in patients 80 and older
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study is testing a targeted medicine called zanubrutinib in people aged 80 and older who have chronic lymphocytic leukemia (CLL) that has not been treated yet. It aims to see if this medication can control the disease while being safe and manageable for older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 80 years of age or older.
- You must have been diagnosed with CLL (or a related condition called SLL) and have never had treatment for it before.
- Your doctor must confirm that you currently need treatment for your CLL.
- You must be in generally good health, able to care for yourself (score 0, 1, or 2 on a standard health scale).
- You must have adequate kidney and liver function, and acceptable blood counts.
- You must not have significant heart disease, bleeding disorders, or recent major surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
This trial tests a three-drug combination for people who have not yet had treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to improve outcomes with a targeted, mostly oral regimen.
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
This trial tests two different combinations of targeted drugs for people with CLL or SLL who have not had prior treatment for their disease. The goal is to see if these combinations are safe and effective.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests two oral medications (sonrotoclax and zanubrutinib) for people newly diagnosed with CLL or SLL who need treatment. The goal is to see if this combination is effective and safe.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.